Title :

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

Author(s) :

Lawless, S. [Auteur]
Sbianchi, G. [Auteur]
Morris, C. [Auteur]
Iacobelli, S. [Auteur]
Bosman, P. [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Reményi, P. [Auteur]
Byrne, J. L. [Auteur]
Mayer, J. [Auteur]
Apperley, J. [Auteur]
Lund, J. [Auteur]
Kobbe, G. [Auteur]
Schaap, N. [Auteur]
Isaksson, C. [Auteur]
Lenhoff, S. [Auteur]
Basak, G. [Auteur]
Touzeau, Cyrille [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Wilson, K. M. O. [Auteur]
González Muñiz, S. [Auteur]
Scheid, C. [Auteur]
Browne, P. [Auteur]
Anagnostopoulos, A. [Auteur]
Rambaldi, A. [Auteur]
Jantunen, E. [Auteur]
Kröger, N. [Auteur]
Schönland, S. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Garderet, Laurent [Auteur]
CHU Pitié-Salpêtrière [AP-HP]

Journal title :

Clinical Lymphoma, Myeloma & Leukemia

Abbreviated title :

Clin Lymphoma Myeloma Leuk

Publication date :

2021-06-25

ISSN :

2152-2669

English keyword(s) :

IgD myeloma
Oligosecretory myeloma
Plerixafor
Progression free survival
Overall survival

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study ...
Show more >Background The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data. Patients This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with “usual” and “rare” myelomas. Results Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis. Conclusion We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T06:36:32Z
2024-02-27T15:59:46Z